Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade from ProteoGenix; catalogue PX-TA1540; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Toripalimab Biosimilar is a monoclonal antibody that specifically targets the programmed cell death protein 1 (PD-1) receptor. It is a biosimilar version of Toripalimab, an FDA-approved immunotherapy for the treatment of various types of cancer. The structure of Toripalimab Biosimilar is similar to that of Toripalimab, with a molecular weight of approximately 150 kDa and a structure consisting of two heavy chains and two light chains.
Toripalimab Biosimilar works by binding to the PD-1 receptor on the surface of T cells, which are important immune cells in the body. The PD-1 receptor plays a crucial role in regulating the immune response by inhibiting T cell activity. By binding to the PD-1 receptor, Toripalimab Biosimilar blocks its inhibitory function and allows the T cells to become activated, leading to a stronger immune response against cancer cells.
Toripalimab Biosimilar has been shown to have a high affinity and specificity for the PD-1 receptor, making it a potent immunotherapy for cancer treatment. It has also been shown to have a longer half-life compared to other anti-PD-1 antibodies, allowing for less frequent dosing and potentially reducing treatment costs.
Toripalimab Biosimilar is primarily used as a therapeutic agent for the treatment of various types of cancer, including melanoma, lung cancer, and bladder cancer. It has also shown promising results in clinical trials for other types of cancer, such as gastric cancer and hepatocellular carcinoma.
As a biosimilar version of Toripalimab, this antibody offers a more affordable option for cancer treatment while maintaining the same efficacy and safety profile. It is also a valuable tool for researchers studying the PD-1 pathway and developing new immunotherapies for cancer treatment.
Toripalimab Biosimilar is a potent anti-PD-1 monoclonal antibody with a similar structure and activity to the FDA-approved Toripalimab. It works by blocking the inhibitory function of the PD-1 receptor, leading to a stronger immune response against cancer cells. This biosimilar version offers a more affordable option for cancer treatment and is also a valuable tool for research in the field of cancer immunotherapy.
Antibody, therapeutic target, Toripalimab Biosimilar, anti-PDCD1, PD1, CD279 mAb, research grade, structure, activity, application.
ProteoGenix catalogue number PX-TA1540. For research use only.
Target: Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Toripalimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
